JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Search

Odonate Therapeutics Inc

Closed

0

Overview

Share price change

24h

Current

Min

Max

Key metrics

By Trading Economics

Odonate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 maj 2026, 22:17 UTC

Earnings

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 maj 2026, 23:47 UTC

Earnings

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 maj 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 maj 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 maj 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 maj 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 maj 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 maj 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 maj 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 maj 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 maj 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Shareholders to Own About 51% of Combined Company

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Board Unanimously Endorsed, Supported Deal

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Deal Unanimously Recommended by Vault Board

4 maj 2026, 22:39 UTC

Acquisitions, Mergers, Takeovers

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 maj 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources to Acquire All Ordinary Shares in Vault

4 maj 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources, Vault Minerals Agree to Merger of Equals

4 maj 2026, 22:37 UTC

Earnings
Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 maj 2026, 22:26 UTC

Earnings
Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 maj 2026, 22:02 UTC

Earnings

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 maj 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 maj 2026, 21:52 UTC

Earnings

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 maj 2026, 21:50 UTC

Earnings

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 maj 2026, 21:50 UTC

Earnings

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 maj 2026, 21:49 UTC

Earnings

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 maj 2026, 21:44 UTC

Earnings

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 maj 2026, 21:44 UTC

Earnings

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 maj 2026, 21:43 UTC

Earnings

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 maj 2026, 21:41 UTC

Earnings

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 maj 2026, 21:40 UTC

Earnings

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Peer Comparison

Price change

Odonate Therapeutics Inc Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Odonate Therapeutics Inc

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
help-icon Live chat